News Posts List
Clinical Data From Phase I Dose-Escalation Study Of NKTR-214
02/22/2017
Nektar Therapeutics (Nasdaq: NKTR) today announced that positive Phase 1 clinical data for Nektar's lead immuno-oncology agent, NKTR-214, in patients with renal cell carcinoma (RCC) were presented at ASCO GU 2017.
#GU17 News You Can Use From The Symposium
02/21/2017
All the news in one place! View the abstracts from the 2017 Genitourinary Cancers Symposium held recently in Orlando, Florida USA.
Genitourinary Cancers Symposium (GUCS) 2017
02/14/2017
In a small study of patients with advanced renal cell carcinoma, nearly half had durable responses after discontinuing checkpoint inhibitors because of toxicities.
Kidney Disease, Cancer, and Obesity
02/14/2017
World Kidney Day promotes education about the harmful consequences of obesity and its association with kidney disease, advocating healthy lifestyle and health policy measures that make preventive behaviors an affordable option. Obesity is also a risk factor, along with smoking and others, that may contribute to the development of renal cancers.
Driven to Cure Donates $200,000 to Advance Rare Kidney Cancer Research
12/22/2016
The donation will support the research of W. Marston Linehan, M.D., Chief of Urologic Surgery and the Urologic Oncology Branch, Center for Cancer Research, at the National Cancer Institute...
What Your Height Says About Your Health
12/22/2016
Yes, how tall or short you are decides a few health issues you may experience in your lifetime, says a study. Read on to know more…
Does IL-2 Still Have a Role in Cancer Immunotherapy?
12/16/2016
Howard L Kaufman discusses the continuing role of high dose interleukin (HD IL-2), an approved therapy for the treatment of metastatic renal cell carcinoma (mRCC)...
Argos Therapeutics Enters into Strategic Research Agreement
12/15/2016
Argos Therapeutics Inc. (ARGS) (“Argos”), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, announced today that it has entered into a strategic research agreement with Personalis, Inc., a precision medicine company, focused on genomics solutions for immuno-oncology, cancer, and genetic disease.
Support Us When Holiday Shopping!
12/13/2016
Support the Kidney Cancer Association by shopping smile.amazon.com. When you do, a percentage of your purchase will be donated to support our charity's mission.
Cancer Drug Tied to Heart Problems
12/12/2016
"All drugs have risks and benefits," noted lead researcher Dr. Ming Hui Chen, an assistant professor of medicine at Harvard Medical School...
News Feed